J&J may consolidate Rx advertising

Share this article:
Johnson & Johnson is considering consolidating advertising and marketing for its pharmaceutical brands into one or possibly two companies, a J&J spokesperson told MM&M.

“We're looking at a number of different options, including perhaps folding it into one or two holding companies,” said Mark Monseau, director of corporate media relations, adding that: “It's too early to speculate what the outcome will be.”

J&J is conducting a global review of its pharma agencies, Advertising Age reported in July. The cross-channel review, including consumer- and professional-focused efforts, excludes PR and does not extend to other product groups.

Like its 250-plus companies scattered across 50-some countries in five continents, J&J's marketing and advertising business is spread around. 

Avenue A | Razorfish is a major J&J ad agency, handling assignments for Ethicon Endo- Surgery, Ortho Women's Health and Urology, Ortho-McNeil Neurologics and a wealth of J&J Consumer Group brands, according to PMD's Product and Agency Index. The digital powerhouse's parent, aQuantive, was purchased by Microsoft last year. 

Among the more traditional holding companies, Interpublic Group's Integrated Communications Corp. handles work on Ortho Women's Health & Urology and J&J Consumer Group brands, while Torre Lazur McCann handles the Harmonic franchise for Ethicon Endo-Surgery. Omnicom's Flashpoint Medica handles the professional assignment for Cordis' Cypher Stent. Altum, a unit of WPP's CommonHealth, services Ortho Biotech's brands, including Procrit, while the network's Noesis handles J&J Consumer Group brands. InVentiv's GSW Worldwide handles much of the Ortho-McNeil Neurologics portfolio. 

Pfizer recently requested for capabilities information from its US consumer and professional advertising and PR agencies, along with some non-roster shops. Pfizer said that so far, it was just looking to understand its agency partners better. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: HealthSpot's teleconnected CEO

Headliner: HealthSpot's teleconnected CEO

Steve Cashman, Founder and CEO, HealthSpot

Recruitment: The New Breed

Recruitment: The New Breed

What do healthcare agencies really want when it comes to potential employees? The answer to that question is in a constant state of flux, as technologies, clients' changing demands and ...

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the September 2014 issue of MM&M, with all text, charts and pictures.